Related Experiment Videos
Viewpoint on handling anti-TNF failure in psoriasis
1Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium, stefanie.bracke@uzgent.be.
Archives of Dermatological Research
|October 8, 2013
Summary
Measuring antidrug antibodies (ADAs) and trough serum drug levels (TSDLs) in psoriasis patients who fail anti-TNF therapy offers a structured approach to guide clinical decisions and optimize treatment outcomes.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Anti-tumor necrosis factor alpha (TNF) agents are used for various diseases, including psoriasis.
- Associations between antidrug antibodies (ADAs), diminished drug levels, and loss of response are noted for anti-TNF therapies.
- Psoriasis patients can experience primary or secondary treatment failure, or adverse reactions to anti-TNF therapy.
Purpose of the Study:
- To investigate the utility of measuring ADAs and TSDLs in psoriasis patients experiencing anti-TNF therapy failure.
- To propose a treatment algorithm for guiding clinical decisions in such cases.
Main Methods:
- A series of ten psoriasis patients with treatment failure or adverse reactions to anti-TNF therapy were studied.
- Serum samples were analyzed for ADAs using radioimmunoassay.
- Serum samples were analyzed for TSDLs using ELISA.
Main Results:
- Measurements of ADAs and TSDLs were performed in the studied patient cohort.
- The data supports the development of a structured approach for managing anti-TNF therapy in psoriasis.
Conclusions:
- Measuring ADAs and TSDLs provides a more structured approach to clinical decision-making for psoriasis patients failing anti-TNF therapy.
- This approach can aid in optimizing treatment strategies for patients with non-response or loss of response.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...